Uniqure B.V. Stock
€4.07
Your prediction
Uniqure B.V. Stock
Pros and Cons of Uniqure B.V. in the next few years
Pros
Cons
Performance of Uniqure B.V. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Uniqure B.V. | -4.710% | -2.513% | -12.740% | -76.734% | -30.164% | -84.421% | -91.256% |
| Novocure Ltd | -3.160% | -0.177% | -7.436% | -80.306% | -21.086% | -93.202% | - |
| Sage Therapeutics Inc. | -1.830% | 2.673% | -32.022% | -71.991% | -39.500% | -80.824% | - |
| Iovance Biotherapeutics Inc. | -2.150% | -1.220% | -21.423% | 111.904% | 39.985% | -57.701% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Uniqure, a company in the biotechnology and medical research industry, presents an interesting financial profile. At a glance, the company shows a consistent increase in total assets and revenue, yet net income has fluctuated significantly over the years with considerable losses in recent periods. This may be indicative of various factors at play within Uniqure, which warrant a deeper investigation to adequately assess the company's financial health.
*Pros: *
Rising total assets and revenue: Over the past three years, Uniqure's total assets and revenue have displayed a steady growth pattern. This indicates that the company has been successful in accumulating valuable assets and generating increased sales, which could be a positive signal for future growth.